Skip to main content

Table 3 RCT, randomized controlled trail; BCG, Bacille Calmette-Guerin; NA, not applicable

From: Safety and efficacy of en bloc transurethral resection versus conventional transurethral resection for primary nonmuscle-invasive bladder cancer: a meta-analysis

 

Subgroup

No. of studies

Heterogeneity

OR/MD [95%CI]

I2 %

p

12-month recurrence

RCT

2

0

0.93

0.98 [0.62, 1.55]

Prospective

1

NA

0.26

0.54 [0.19, 1.58]

Retrospective

6

0

0.06

0.59 [0.33, 1.03]

Epirubicin

5

0

0.68

0.92 [0.61, 1.37]

Mitomycin

2

23

0.04

0.31 [0.10, 0.93]

Pirarucin

1

NA

0.65

0.79 [0.29, 2.18]

Epirubicin + BCG

1

NA

0.26

0.77 [0.55, 1.07]

24-month recurrence

RCT

2

0

0.19

0.70 [0.41, 1.19]

Prospective

2

19

0.02

0.43 [0.21, 0.89]

Retrospective

10

0

0.006

0.64 [0.47, 0.88]

Epirubicin

7

0

0.13

0.71 [0.45, 1.10]

Mitomycin

4

0

0.01

0.61 [0.41, 0.90]

Pirarucin

2

0

0.14

0.65 [0.36, 1.16]

BCG

1

NA

0.03

0.24 [0.07, 0.84]

36-month recurrence

 

4

58

0.32

0.72 [0.37, 1.39]

Same site recurrence

 

5

0

0.10

0.49 [0.21, 1.14]

Recurrence

Low-risk

5

0

0.96

1.01 [0.63, 1.63]

Intermediate-risk

4

0

0.26

0.76 [0.47, 1.23]

High-risk

3

0

0.76

0.82 [0.24, 2.85]